| Literature DB >> 30947271 |
Sumon Kumar Das1,2,3, Syeda Momena Afsana1, Shahriar Bin Elahi1, Mohammod Jobayer Chisti1, Jui Das4, Abdullah Al Mamun2, Harold David McIntyre2,5,6, Tahmeed Ahmed1, Abu Syed Golam Faruque1, Mohammed Abdus Salam1.
Abstract
OBJECTIVE: The objective of this study was to describe the age and sex-specific prevalence of renal insufficiency, and observe its trends over a decade at an urban Bangladesh setup.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30947271 PMCID: PMC6448896 DOI: 10.1371/journal.pone.0214568
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Overall and sex-specific distribution of renal insufficiency stages following CKD-EPI equation by year and by age groups.
Distribution of renal insufficiency stages in different age groups by CKD-EPI formula in 2006 and 2015.
| Stage-2 | Stage-3 | Stage-4 | Stage-5 | Overall | Stage-2 | Stage-3 | Stage-4 | Stage-5 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age group | Year | N | n | % | n | % | n | % | n | % | |||||
| *<24Y | 2006 | 171 | 21 | 12.28 | 8 | 4.68 | 2 | 1.17 | 2 | 1.17 | 4.68 | 1.81 | 6.25 | 3.50 | 10.50 |
| 2015 | 801 | 38 | 4.74 | 50 | 6.24 | 7 | 0.87 | 21 | 2.62 | ||||||
| 24-28Y | 2006 | 333 | 32 | 9.61 | 34 | 10.21 | 20 | 6.01 | 8 | 2.4 | 4.76 | 3.53 | 2.06 | 1.30 | 3.50 |
| 2015 | 1,586 | 113 | 7.12 | 70 | 4.41 | 26 | 1.64 | 28 | 1.77 | ||||||
| 29-33Y | 2006 | 448 | 46 | 10.27 | 41 | 9.15 | 13 | 2.9 | 19 | 4.24 | 5.17 | 4.46 | 1.98 | 3.00 | 2.21 |
| 2015 | 2,317 | 205 | 8.85 | 81 | 3.5 | 39 | 1.68 | 42 | 1.81 | ||||||
| 34-38Y | 2006 | 677 | 78 | 11.52 | 60 | 8.86 | 20 | 2.95 | 38 | 5.61 | 4.93 | 4.78 | 3.02 | 4.00 | 2.45 |
| 2015 | 3,339 | 373 | 11.17 | 181 | 5.42 | 80 | 2.4 | 93 | 2.79 | ||||||
| 39-43Y | 2006 | 793 | 107 | 13.49 | 76 | 9.58 | 59 | 7.44 | 51 | 6.43 | 5.26 | 6.04 | 3.67 | 1.92 | 1.75 |
| 2015 | 4,171 | 646 | 15.49 | 279 | 6.69 | 113 | 2.71 | 89 | 2.13 | ||||||
| 44-48Y | 2006 | 881 | 209 | 23.72 | 142 | 16.12 | 42 | 4.77 | 48 | 5.45 | 5.96 | 5.43 | 3.39 | 4.19 | 2.98 |
| 2015 | 5,248 | 1,134 | 21.61 | 482 | 9.18 | 176 | 3.35 | 143 | 2.72 | ||||||
| 49-53Y | 2006 | 1,225 | 308 | 25.14 | 221 | 18.04 | 94 | 7.67 | 101 | 8.24 | 4.25 | 4.40 | 3.29 | 2.70 | 1.95 |
| 2015 | 5,206 | 1,355 | 26.03 | 727 | 13.96 | 254 | 4.88 | 197 | 3.78 | ||||||
| 54-58Y | 2006 | 1,138 | 316 | 27.77 | 255 | 22.41 | 124 | 10.9 | 122 | 10.72 | 4.57 | 5.15 | 3.77 | 3.20 | 2.52 |
| 2015 | 5,196 | 1,628 | 31.33 | 962 | 18.51 | 397 | 7.64 | 307 | 5.91 | ||||||
| 59-63Y | 2006 | 952 | 287 | 30.15 | 213 | 22.37 | 139 | 14.6 | 105 | 11.03 | 5.32 | 5.86 | 5.84 | 3.37 | 3.50 |
| 2015 | 5,069 | 1,683 | 33.2 | 1,243 | 24.52 | 468 | 9.23 | 368 | 7.26 | ||||||
| 64-68Y | 2006 | 782 | 219 | 28.01 | 210 | 26.85 | 112 | 14.32 | 127 | 16.24 | 4.71 | 5.87 | 5.45 | 3.45 | 1.98 |
| 2015 | 3,680 | 1,286 | 34.95 | 1,144 | 31.09 | 386 | 10.49 | 252 | 6.85 | ||||||
| ≥69Y | 2006 | 920 | 267 | 29.02 | 319 | 34.67 | 144 | 15.65 | 149 | 16.2 | 4.91 | 6.00 | 5.28 | 4.10 | 2.58 |
| 2015 | 4,519 | 1,601 | 35.43 | 1,684 | 37.26 | 591 | 13.08 | 384 | 8.5 | ||||||
*ratio of overall number of individual assessed serum creatinine and number of CKD stage 2 to stage-5 between 2015 and 2006
Overall and sex-specific association of eGFR following CKD-EPI formula.
| Coef. | 95% CI | ||
|---|---|---|---|
| LL | UL | ||
| -1.32 | -1.33 | -1.31 | |
| Male (N = 123957) | -1.15 | -1.16 | -1.14 |
| Female (N = 94931) | -1.56 | -1.57 | -1.55 |
| -1.35 | -1.37 | -1.33 | |
| Male (N = 18165) | -1.20 | -1.23 | -1.18 |
| Female (N = 12417) | -1.58 | -1.62 | -1.54 |
*adjusted for age, sex and years;
#adjusted for age, sex, years and blood glucose.
Sex was removed in sex specific analyses
Overall and sex-specific risk of renal insufficiency following CKD-EPI formula.
| Overall (N = 218888) | Male (N = 123957) | Female (N = 94931) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | OR | 95% CI | ||||
| Stage-2 | LL | UL | LL | UL | LL | UL | |||
| <45Y | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| 45-48Y | 2.34 | 2.25 | 2.44 | 2.25 | 2.14 | 2.36 | 2.49 | 2.32 | 2.67 |
| 49-53Y | 3.64 | 3.50 | 3.77 | 3.31 | 3.17 | 3.47 | 4.10 | 3.85 | 4.37 |
| 54-58Y | 6.00 | 5.79 | 6.23 | 5.56 | 5.30 | 5.82 | 6.58 | 6.18 | 7.01 |
| 59-63Y | 8.68 | 8.34 | 9.04 | 8.32 | 7.91 | 8.76 | 9.59 | 8.96 | 10.26 |
| 64-68Y | 13.18 | 12.54 | 13.86 | 13.24 | 12.39 | 14.15 | 14.10 | 13.01 | 15.28 |
| ≥69Y | 37.01 | 34.73 | 39.45 | 35.96 | 33.08 | 39.10 | 41.91 | 37.88 | 46.36 |
| Stage-3 | |||||||||
| <45Y | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| 45-48Y | 2.27 | 2.15 | 2.38 | 1.94 | 1.81 | 2.09 | 2.73 | 2.53 | 2.94 |
| 49-53Y | 3.71 | 3.54 | 3.88 | 2.84 | 2.67 | 3.03 | 4.95 | 4.62 | 5.29 |
| 54-58Y | 6.98 | 6.67 | 7.29 | 5.93 | 5.58 | 6.29 | 8.42 | 7.88 | 9.00 |
| 59-63Y | 12.42 | 11.86 | 13.00 | 11.68 | 10.99 | 12.41 | 13.55 | 12.63 | 14.53 |
| 64-68Y | 22.35 | 21.18 | 23.59 | 23.99 | 22.30 | 25.81 | 20.73 | 19.11 | 22.48 |
| ≥69Y | 75.56 | 70.73 | 80.72 | 78.31 | 71.73 | 85.50 | 71.14 | 64.32 | 78.69 |
| Stage-4 | |||||||||
| <45Y | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| 45-48Y | 2.26 | 2.09 | 2.44 | 1.76 | 1.57 | 1.97 | 2.84 | 2.56 | 3.15 |
| 49-53Y | 3.82 | 3.57 | 4.08 | 2.87 | 2.60 | 3.16 | 4.97 | 4.53 | 5.45 |
| 54-58Y | 7.20 | 6.76 | 7.66 | 5.25 | 4.79 | 5.75 | 9.52 | 8.72 | 10.39 |
| 59-63Y | 13.29 | 12.48 | 14.16 | 13.05 | 11.97 | 14.23 | 13.58 | 12.39 | 14.89 |
| 64-68Y | 21.63 | 20.14 | 23.23 | 20.88 | 18.89 | 23.08 | 22.55 | 20.37 | 24.96 |
| ≥69Y | 82.91 | 76.68 | 89.63 | 79.84 | 71.82 | 88.75 | 85.06 | 75.79 | 95.46 |
| Stage-5 | |||||||||
| <45Y | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| 45-48Y | 1.98 | 1.83 | 2.15 | 1.39 | 1.23 | 1.57 | 2.89 | 2.58 | 3.24 |
| 49-53Y | 3.36 | 3.13 | 3.61 | 2.23 | 2.01 | 2.47 | 5.13 | 4.64 | 5.67 |
| 54-58Y | 6.52 | 6.10 | 6.96 | 4.13 | 3.76 | 4.55 | 10.15 | 9.23 | 11.17 |
| 59-63Y | 9.95 | 9.30 | 10.66 | 8.47 | 7.72 | 9.29 | 12.21 | 11.02 | 13.53 |
| 64-68Y | 18.00 | 16.69 | 19.41 | 15.62 | 14.07 | 17.35 | 21.69 | 19.41 | 24.23 |
| ≥69Y | 55.92 | 51.48 | 60.74 | 47.37 | 42.40 | 52.91 | 67.90 | 59.93 | 76.92 |
NB: Stage -1 considered as reference group; adjusted for sex and years; sex was removed in sex specific analyses
OR: Odds ratio; CI: Confidence interval; LL: Lower limit; UL: Upper limit; Y: Years
Fig 2Distribution of eGFR at menopausal age among females and males at same age.